8 News & Press Releases found
Ariana Pharma News
-
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading ...
-
AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical ...
-
Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial ...
-
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ...
-
Anavex Life Sciences and Ariana Pharma present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 ...
-
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to ...
-
Ariana appoints pharmaceutical industry drug development veteran
Ariana, a leading eXplainable Artificial Intelligence (AI) drug development company, is delighted to announce the appointment of Dr. Hichem Chakroun as Executive VP, Clinical Development. As EVP, Hichem will apply his industry expertise and ...
-
Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune ...